When was Tandem Diabetes founded?

Tandem Diabetes was founded in 2008 and raised its 1st funding round 2 years after it was founded.

Where is Tandem Diabetes located?

Tandem Diabetes is headquartered in San Diego, United States. It is registered at Práčská 1881 10600 Praha.

How many employees does Tandem Diabetes have?

As of Sep 30, 2026, the latest employee count at Tandem Diabetes is 2204.

Is Tandem Diabetes a funded company?

Tandem Diabetes is a funded company, having raised a total of $101M across 6 funding rounds to date. The company's 1st funding round was a $***** Series C round, raised on Jan 07, 2010.

When was the latest funding round of Tandem Diabetes?

Tandem Diabetes' latest funding was a $***** Post IPO round on May 15, 2020, with participation from 0 investor.

What is the annual revenue of Tandem Diabetes?

Annual revenue of Tandem Diabetes is more than $1B as on Dec 31, 2025

Where does Tandem Diabetes rank among its competitors?

Tandem Diabetes ranks 1st amongst 48 active competitors, of which 9 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Kaleido, which secured $13M in Jan, 2026.

Who are the top competitors of Tandem Diabetes?

Tandem Diabetes' top competitors include Insulet, Ypsomed and Kaleido. Among them, Kaleido secured the most recent funding round in January, 2026.

Tandem Diabetes - 2026 Company Profile, Funding, Competitors & Financials

Tandem Diabetes is a public company based in San Diego (United States), founded in 2008. It operates as a Developer of devices for continuous glucose monitoring and manual insulin delivery. Tandem Diabetes has raised $101M in funding. The company has 48 active competitors, including 9 funded and 13 that have exited. Its top competitors include companies like Insulet, Ypsomed and Kaleido.

Company Details

Tandem Diabetes is a developer of devices for continuous glucose monitoring and manual insulin delivery. It develops insulin pumps & other products and services that bring innovation, convenience & style to diabetes management. The first product, the t: slim Insulin Pump, features a sleek, modern design, intuitive touch-screen interface, and a rechargeable lithium-polymer battery. The company claims that this makes them closer to producing a fully automated closed-loop automated insulin delivery device that will not require human intervention to release insulin.

Website: www.tandemdiabetes.com
Social
Registered Address: Práčská 1881 10600 Praha

Key Metrics

Founded Year

2008

Location

San Diego, United States

Stage

Public

Total Funding

$101M in 6 rounds

Latest Funding Round

Post IPO, May 15, 2020, $*****

Investors

Gynther Capital & 6 more

Ranked

1^st among 48 active competitors

Annual Revenue

$1B+ as on Dec 31, 2025

Employee Count

2,204 as on Sep 30, 2026

Investment & Acquisitions

Advanced Microfluidics & 4 more

Similar Companies

Kaleido & 22 more

Exit Details

Public

View Tandem Diabetes' full profile

Tandem Diabetes is associated with 6 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
L I E R, spol. s r.o. CIN: 45802670 , Czech Republic, Active	Jun 29, 1992	-	-
NL.CZ, spol. s r.o. CIN: 25960369 , Czech Republic, Active	Nov 06, 2001	-	-
Tandem Diabetes Care, Inc. CIN: 12043275085 , United States, Active	Nov 12, 2013	-	-	-
TANDEM DIABETES CARE INC CIN: 1438133 , United States, Active	Jan 06, 2008	$1B+ (As on Dec 31, 2025)	-	-
TANDEM, INC CIN: 560992306 , United States, Active	Dec 31, 1999	-	272 (As on Dec 31, 2024)	-
TANDEM DIABETES CARE, INC CIN: 204327508 , United States, Active	Dec 31, 1999	-	2516 (As on Dec 31, 2024)	-

Tandem Diabetes got listed on Nov 14, 2013.

Click here to take a look at Tandem Diabetes's IPO in detail

Tandem Diabetes has raised a total funding of $101M over 6 rounds. Its first funding round was on Jan 07, 2010. Tandem Diabetes has 7 institutional investors.

Here is the list of recent funding rounds of Tandem Diabetes:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 15, 2020	9341863	Post IPO	9772750	5541963	4208670	4819823
Jan 16, 2018	8636351	Post IPO	2423785	8889211	5876320	4962983
Jan 12, 2016	4195757	Conventional Debt	7839638	4865275	9920212	CRG

Access funding benchmarks and valuations. Sign up today!

View details of Tandem Diabetes's funding rounds and investors

Tandem Diabetes' employee count trend

Tandem Diabetes has 2,204 employees as of Sep 26. Here is Tandem Diabetes's employee count trend over the years:

Employee count trend for Tandem Diabetes

Uncover Tandem Diabetes' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Tandem Diabetes include Insulet, Ypsomed and Kaleido. Here is the list of Top 10 competitors of Tandem Diabetes, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Tandem Diabetes 2008, San Diego (United States), Public	Developer of devices for continuous glucose monitoring and manual insulin delivery	$101M	Gynther Capital, Domain Associates & 5 others	77/100
2nd	Insulet 2000, Boston (United States), Public	Manufacturer of wearable, tubeless insulin delivery systems for diabetes management	$120M	Federated Hermes, Piper Jaffray & 13 others	74/100
3rd	Ypsomed 2003, Burgdorf (Switzerland), Acquired	Developer of self delivery injection systems and diabetes care systems	$7.45M	BV Partners, BV Group	64/100
4th	Kaleido 2013, Utrecht (Netherlands), Series D	Developer of insulin therapy for treating diabetes	$183M	Life Sciences Partners, Innovation Industries ... & 10 others	64/100
5th	Microtech Medical 2011, Hangzhou (China), Public	Medical devices developer for diabetes care	$88.2M	Tencent, IDG Capital & 9 others	58/100
6th	Sigrid Therapeutics 2014, Stockholm (Sweden), Series C	Developer of therapies to treat metabolic and chronic lifestyle diseases	$27M	Irrus Investments, Joyance Partners & 9 others	57/100
7th	Omnipod 1999, Acton (United States), Unfunded	Provider of smart wearable disposable pod provides insulin delivery	-	-	54/100
8th	Embecta 2022, Parsippany (United States), Public	Manufacturer of insulin delivery solutions, including pen needles and insulin syringes	-	-	53/100
9th	Modular Medical 2017, San Diego (United States), Series A	Developer of insulin pump for insulin delivery	$5.28M	-	52/100
10th	Medtronic Diabetes 1993, Northridge (United States), Unfunded	Diabetes management solutions: insulin pumps, smart pens, and continuous glucose monitoring	-	-	49/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Tandem Diabetes's competitors? Click here to see the top ones

Tandem Diabetes has made 1 investments in companies including CeQur. Tandem Diabetes has also acquired 4 companies including Advanced Microfluidics and Amf Medica.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Dec 13, 2022	Acquisition	Advanced Microfluidics	2014	Ecublens (Switzerland)
Dec 13, 2022	Acquisition	Amf Medica	2008	Grafenau (Germany)
Jul 21, 2022	Acquisition	Capillary Biomedical	2014	Irvine (United States)